CWI1-2 |
Catalog No.GC68916
One-Click Copy Product Info
|
CWI1-2 is a selective inhibitor of the m6A reader protein IGF2BP2, disrupting the interaction between IGF2BP2 and m6A-modified target transcripts.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2408590-36-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
CWI1-2 is a selective inhibitor of the m6A reader protein IGF2BP2, disrupting the interaction between IGF2BP2 and m6A-modified target transcripts [1] [2]. The IC50 at the cellular level ranges from 203.1 to 781.6 nM[1] . This inhibitor is primarily used for research in acute myelocytic leukemia (AML) due to its promising anti-leukemic properties [1].
CWI1-2 exerts anti-leukemic effects by targeting IGF2BP2, inducing apoptosis and differentiation in leukemia cells. The IC50 at the cellular level ranges from 203.1 to 781.6 nM [1]. In AML cell lines, CWI1-2 at concentrations of 0.1 to1 μM over 48h inhibits cell growth and induces apoptosis [3].
CWI1-2 (5 mg/kg, intravenous injection, daily for 7-10 days) significantly reduced leukemia progression and prolonged survival in BMT recipient mice. Treatment results in a marked reduction in leukemia cell burden without significant changes in body weight [3].
References:
[1]. Zhu TY, Hong LL, Ling ZQ. Oncofetal protein IGF2BPs in human cancer: functions, mechanisms and therapeutic potential. Biomark Res. 2023 Jun 6;11(1):62. doi: 10.1186/s40364-023-00499-0.
[2]. Wang M, Chao M, Han H, et al. Hinokiflavone resists HFD-induced obesity by promoting apoptosis in an IGF2BP2-mediated Bim m6A modification dependent manner. J Biol Chem. 2024 Sep;300(9):107721. doi: 10.1016/j.jbc.2024.107721. Epub 2024 Aug 29. PMID: 39214307; PMCID: PMC11465056.
[3]. Weng H, Huang F, Yu Z, et al. The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. Cancer Cell. 2022 Dec 12;40(12):1566-1582.e10. doi: 10.1016/j.ccell.2022.10.004.
| Cell experiment [1]: | |
Cell lines | THP1 |
Preparation Method | Cells were treated with CWI1-2 (0.1-1 μM) for 48 h, cell viability was then evaluated by MTT assay. The medium was then changed with MTT solution (0.5mg/ml) in DMEM or RPMI without phenol red and FBS; cells were incubated at 37°C for 30 min and violet precipitate was dissolved with isopropanol. Absorbance at 550nm was measured through an EnSpire Multimode Plate reader. |
Reaction Conditions | 0.1 to1 μM, 48 hours |
Applications | Treatment of THP1cells with CWI1-2 induced dramatic cell differentiation and apoptosis in a concentration-dependent manner |
| Animal experiment [2]: | |
Animal models | B6.SJL (CD45.1) mice |
Preparation Method | B6.SJL (CD45.1) mice were performed bone marrow transplants (BMTs) using blast cells from MAP-induced leukemia mice or C1498 murine AML cells. Following the transplantation, CWI1-2 is administered at a dosage of 5 mg/kg daily via intravenous injection for a period of 7 to 10 days. Peripheral blood (PB) samples are then collected, and flow cytometric analysis is conducted to assess leukemia engraftment. |
Dosage form | 5 mg/kg/d, 7-10 days, i.v. |
Applications | CWI1-2 treatment significantly delayed leukemia onset and prolonged the survival of BMT recipient mice |
References: [1]. Weng H, Huang F, Yu Z, et al. The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. Cancer Cell. 2022 Dec 12;40(12):1566-1582.e10. doi: 10.1016/j.ccell.2022.10.004. | |
| Cas No. | 2408590-36-1 | SDF | |
| Formula | C22H17Cl3N6O3 | M.Wt | 519.77 |
| Solubility | DMSO : 100 mg/mL (192.39 mM; Need ultrasonic) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9239 mL | 9.6196 mL | 19.2393 mL |
| 5 mM | 384.8 μL | 1.9239 mL | 3.8479 mL |
| 10 mM | 192.4 μL | 962 μL | 1.9239 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)